The American Journal of Managed Care7d
FDA Approves First Subcutaneous Nivolumab Injection in Most Solid Tumors
FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.
Targeted Oncology13d
FDA Approves Subcutaneous Nivolumab Across Existing Solid Tumor Indications
On December 27, 2024, subcutaneous nivolumab (Opdivo Qvantig) was approved by the FDA in all previously approved adult solid ...
Renal & Urology News3d
FDA Approves Opdivo Qvantig, a Subcutaneous Formulation of Nivolumab
The FDA has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), a new subcutaneous injection formulation of Opdivo.
FDA approves subcutaneous opdivo qvantig for most solid tumor indications
The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for ...
Targeted Oncology6d
FDA’s December 2024 Oncology Approvals and Designations
On December 20, 2024, the FDA granted accelerated approval to the combination of encorafenib (Braftovi), cetuximab (Erbitux), ...
Becker's Hospital Review10d
FDA approves injectable version of popular cancer drug
The FDA approved a subcutaneous injection version of Bristol Myers Squibb nivolumab and hyaluronidase-nvhy for the treatment of several cancers including melanoma, non-small cell lung cancer and renal ...
The Pharma Letter12d
FDA approves new injectable version of Opdivo
The US Food and Drug Administration (FDA) on Friday approved nivolumab and hyaluronidase-nvhy, under the trade name Opdivo ...
FiercePharma7d
Bristol Myers celebrates 10 years of Opdivo with FDA approval for subcutaneous version
Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...
Bristol-Myers Squibb : FDA Approves Opdivo Qvantig For Subcutaneous Use In Adult Solid Tumors
Bristol Myers Squibb (BMY) announced Friday that the U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and ...
Pharmaceutical Technology4d
Nivolumab biosimilar by Amgen for Metastatic Melanoma: Likelihood of Approval
Nivolumab biosimilar is under clinical development by Amgen and currently in Phase III for Metastatic Melanoma.
Cure Today1d
Understanding the Benefit of Subcutaneous Versus IV Opdivo in Patients With Solid Tumors
Dr. Eric K. Singhi discusses the benefit of subcutaneous immunotherapy following the FDA approval of subcutaneous Opdivo for ...
Monthly Prescribing Reference8d
FDA Approves Opdivo Qvantig, a Subcutaneous Formulation of Nivolumab
Opdivo Qvantig combines nivolumab, a programmed death receptor ... available as a solution for intravenous (IV) infusion. The approval of Opdivo Qvantig was supported by data from the randomized ...